First Tracks climbs on ‘impressive’ celiac study data

Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential. 

By Delilah Alvarado • Oct. 12, 2026

Parkinson’s cell therapy developer files to go public

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.

By Jacob Bell • Oct. 12, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

By Ben Fidler • Oct. 12, 2026

FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.

By BioPharma Dive staff • Oct. 9, 2026

This week in charts: What’s driving biotech’s recent pullback?

The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks of late and the frenetic pace of startup buyouts this year. 

By Gwendolyn Wu • Oct. 9, 2026

TRex Bio prices $117M IPO to support immune drug work

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

By Gwendolyn Wu • Oct. 9, 2026

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.

By BioPharma Dive staff • Oct. 7, 2026

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

By Jacob Bell • Oct. 7, 2026

Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds

The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.

By Gwendolyn Wu • Oct. 6, 2026

ArriVent collapses on disappointing lung cancer data

More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share. 

By Delilah Alvarado • Oct. 6, 2026

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

By Jonathan Gardner • Oct. 6, 2026

The top biopharma conferences in 2027

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.

By Ben Fidler • Oct. 6, 2026

Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medicine.

By Ben Fidler • Oct. 5, 2026

This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking

The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.

By Jonathan Gardner • Oct. 2, 2026

Lilly, Foghorn part ways; Wave’s FDA-approved plans

The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

By Gwendolyn Wu • Oct. 1, 2026

Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame. 

By Jonathan Gardner • Sept. 30, 2026

PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval

A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

By Ben Fidler • Sept. 30, 2026

An AI agent made a tiny drug R&D mistake. Then it kept going.

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?

By Sy Mukherjee • Sept. 30, 2026

Beam sues 2 biotechs, alleging theft of base editing trade secrets

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

By Gwendolyn Wu • Sept. 29, 2026

Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.

By Jonathan Gardner • Sept. 29, 2026

UniQure tumbles with latest data for Huntington’s gene therapy

Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."

By Jacob Bell • Sept. 29, 2026

ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’

Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.

By Gwendolyn Wu • Sept. 29, 2026

AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

By Ben Fidler • Sept. 29, 2026

Kodiak skyrockets on positive study data for 2 eye drugs

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

By Jonathan Gardner • Sept. 28, 2026

This week in charts: Novo’s rise and fall and AI biotechs’ big haul

The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.

By Gwendolyn Wu • Sept. 25, 2026